# Triumvira Immunologics Updates

## Presentation of Clinical Data  
**Date:** June 28, 2023  
**Locations:** AUSTIN, Texas; HAMILTON, ON; SOUTH SAN FRANCISCO, Calif.  
**Announcement:** Triumvira Immunologics will present clinical data on its lead asset TAC01-HER2 for HER2 positive solid tumors at the **2023 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer** in Barcelona, Spain, held from June 28 – July 1, 2023. The presentation will showcase findings from the ongoing Phase I/II trial of TAC01-HER2 among patients with relapsed or refractory solid tumors.

### Quote  
> "We are honored to share our latest advancements in precision cell therapy at ESMO World Congress. Our innovative and well-differentiated TAC01-HER2 cell therapy holds great promise in the treatment of HER2-positive solid tumors," said **Deyaa Adib, M.D.**, Chief Medical Officer.

---

## Positive Data Presentation  
**Date:** May 31, 2023  
**Locations:** AUSTIN, Texas; HAMILTON, ON; SOUTH SAN FRANCISCO, Calif.  
**Announcement:** Positive data from the Phase I/II trial of autologous TAC01-HER2 in refractory solid tumors (TACTIC-2) will be presented at the **2023 American Society Of Clinical Oncology (ASCO) Annual Meeting** in Chicago from June 2-6. **Benjamin L. Schlechter, MD**, will highlight updated clinical data demonstrating the potential of TAC01-HER2.

### Quote  
> "We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said **Deyaa Adib, M.D.**.

---

## Updates at ASCO 2023  
**Date:** May 16, 2023  
**Announcement:** Triumvira will present clinical data on TAC01-HER2 during the ASCO Annual Meeting highlighting updated clinical data from the ongoing Phase I/II trial.

### Quote  
> "We are excited to present the latest clinical data from our Phase I/II trial of TAC01-HER2 in refractory solid tumors at the upcoming ASCO meeting..." said **Deyaa Adib, M.D.**.

---

## AACR Annual Meeting Presentation  
**Date:** April 18, 2023  
**Announcement:** Triumvira will present data at the **2023 AACR Annual Meeting** on TAC01-HER2 for HER2 positive solid tumors, including updated clinical data from the ongoing TACTIC-2 trial and preclinical data on allogeneic HER2-TAC T cell products.

### Presentation Details  
- **Title:** A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors  
- **Authors:** Ecaterina E. Dumbrava, MD; Daniel Olson, MD; Samuel Saibil, MD; Brooke Pieke; Mridula A. George, MD; Riemke Bouvier; Kelly Gruber; Kara Moss; Nathan Ternus; Maria Apostolopoulou; Deyaa Adib, MD; Benjamin L. Schlechter, MD.

---

## Collaboration with Merck  
**Date:** April 18, 2023  
**Announcement:** Triumvira announced a clinical trial collaboration and supply agreement with **Merck** to evaluate TAC01-HER2 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab).

### Quote  
> "We believe the addition of an immune checkpoint inhibitor, such as KEYTRUDA, to TAC01-HER2 will effectively release inhibitory PD-L1/PD1 signaling in T cells..." said **Paul Lammers, M.D.**.

---

## Updated Positive Clinical Data   
**Date:** November 10, 2022  
**Announcement:** Updated data from the ongoing TACTIC-2 Phase 1/2 trial of TAC01-HER2 will be shared at the **Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting**.

### Interim Data Highlights  
- TAC01-HER2 is well-tolerated with clinical activity observed in higher dosing cohorts.
- Notable disease control rate of 67% in the third cohort (n=3).
- Patients demonstrate stable disease, indicating potential clinical benefit.

---

## Preclinical Data Presentation  
**Date:** November 9, 2022  
**Announcement:** Triumvira presented preclinical data for investigational TAC-T cell therapies including CLDN18.2-TAC T and GUCY2C-TAC T.

### Quote  
> "We are encouraged by our preclinical results... our proprietary TAC technology is versatile and can achieve effective and specific tumor targeting," said **Andreas Bader, Ph.D.**.

---

## Leadership Update  
**Date:** October 24, 2022  
**Announcement:** Appointment of **Robert Williamson** as President and Chief Business Officer, responsible for business development and strategy.

### Quote  
> "We are delighted to welcome Rob to the team and look forward to advancing Triumvira’s mission," said **Paul Lammers, M.D.**.

---